Additionally, patients with a gain-of-function mutation in the hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene, which codes for the rate-limiting enzyme of the cholesterol synthesis pathway, do not develop kidney disease [13]. Here, HMGCR is linked to kidney disorder.